---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-22-011124"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:14:04.303043+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix Q3 net loss widens to $29M on higher R&D spend; cash at $140M

## Summary
- Net loss $29.0M ($0.69/sh) vs $18.5M ($1.60/sh) in Q3 2021; share count rose to 41.9M from 11.6M.
- Cash and equivalents $140M at Sept 30, 2022, down from $178.7M at Dec 31, 2021.
- R&D expenses $22.2M in Q3 2022 vs $13.1M in Q3 2021, driven by clinical and manufacturing costs.
- Raised $15.0M in Oct 2022 via private placement of Series A/B convertible redeemable preferred stock.
- Interim data from Phase 3 fibromyalgia and Phase 2 Long COVID TNX-102 SL studies expected in Q2 2023.

## SEC filing metadata
- accession: 0001387131-22-011124
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/0001387131-22-011124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/tnxp-8k_110722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-22-011124
- JSON: https://secwatch.observer/filing/0001387131-22-011124.json
- Plain text: https://secwatch.observer/filing/0001387131-22-011124.txt

## Key facts
- Earnings Releases
  Tonix Pharmaceuticals Holding Corp. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/0001387131-22-011124-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.